NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan
NanoViricides, Inc. Has Filed its Quarterly Report
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025
NanoViricides Engages CRO for Phase II Clinical Trial
NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.